YULIYA IHLITSKAYA: Open Payments
NPI 1558819664 · CHICAGO, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$617 in 28 payments from 8 companies in 2025. Trend: 2023 $332 · 2024 $641 · 2025 $617
Food & beverage: $617
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $299 |
| Vanda Pharmaceuticals Inc. | 4 | $97 |
| Janssen Pharmaceuticals, Inc | 2 | $53 |
| ABBVIE INC. | 2 | $48 |
| Noven Therapeutics, LLC | 2 | $42 |
| Supernus Pharmaceuticals, Inc. | 2 | $39 |
| Alkermes, Inc. | 1 | $22 |
| Neos Therapeutics, LP | 1 | $17 |
Products named: CAPLYTA, FANAPT, VRAYLAR, Xelstrym, Qelbree, INVEGA SUSTENNA, LYBALVI, SPRAVATO.
Industry payments across IL — which companies pay providers there.
